PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper

The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.